Start Page
Κλίκ για μεγέθυνση
The WANTAI SARS-CoV-2 NAbs ELISA is an enzyme-linked immunosorbent assay for the quantitative detection of neutralizing antibodies to SARS-CoV-2 virus in human serum or plasma. The WANTAI SARS-CoV-2 NAbs ELISA is
intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating prior infection, or as an aid in individual vaccination management decisions. The quantitative result obtained with this kit is as a reference for clinician only, cannot be used as the sole basis for further individual vaccination and treatment.

Principle of the test 
The WANTAI SARS-CoV-2 NAbs ELISA employs solid phase, competitive ELISA method for detection of neutralizing antibodies to SARS-CoV-2 in two-step incubation procedure. Polystyrene microwell strips are pre-coated with genetic recombinant antigens of SARS-CoV-2 spike protein. During the first incubation step, SARS-CoV-2 specific neutralizing antibodies, if present, will be bound to the solid phase pre-coated antigens. The wells are washed to remove unbound serum proteins and then, S-RBD antibodies conjugated to horseradish peroxidase (HRP-Conjugate) is added. During the second incubation step, these HRP-conjugated antibodies will compete with the neutralizing antibodies to bind to the coated antigens. If the concentration of the neutralizing antibodies in the sample is high, the HRP-conjugated S-RBD antibodies will bind less to the coated antigens, and the blue colored products generated will show light color after chromogens are added, otherwise, the color will be deep. The concentration of neutralizing
antibodies can be calculated by standard concentration and absorbance value (A value).
This kit contains reagents sufficient for testing of maximum of 82 specimens in a test run.

Φόρμα Ενδιαφέροντος

Διεύθυνση: Kαισαρείας 6, 11527, Αθήνα  /  2ος Οροφος  /  Τηλ: 210 7754303 & 210 7756251  /  Φαξ: 210 7472725  /  Εmail: ndd@ndd.gr


Login /Sitemap

Copyright © 2013 - 2024 NDD - New Diagnostic Dimension